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doi:10.1016/j.jtcvs.2006.01.005ackground: Maintaining hemostasis in patients with end-stage heart failure under-
oing cardiac surgery is always challenging. These patients have chronic hepatic
nsufficiency, resulting in derangement of coagulation. In addition, they are com-
only receiving both systemic anticoagulation (warfarin or heparin) and antiplatelet
herapy. The introduction of antifibrinolytics has had a significant effect on post-
perative coagulopathy. We report fatal pulmonary microthrombi in patients receiv-
ng antifibrinolytics who developed suprasystemic pulmonary artery pressures and
ight heart failure that was impossible to overcome despite insertion of a right
entricular assist device.
ethods: We reviewed the surgical procedure and autopsy reports to identify
atients with high pulmonary artery pressures caused by pulmonary microthrombi
fter a cardiac surgical procedure for end-stage heart failure. Patient demographics
nd preoperative, intraoperative, and postoperative variables were collected from a
etrospective review of the patients’ medical records.
esults: We identified 9 patients (7 men and 2 women; mean age, 45  16 years)
ho died of pulmonary microthrombi after cardiac surgery between January 1997
nd January 2004. Surgical procedures included 5 left ventricular assist device
mplantations, 2 heart transplantations, and 2 left ventricular reconstructions with
itral valve repair or replacement. Eight patients received aprotinin, and 1 patient
eceived -aminocaproic acid immediately before and during cardiopulmonary
ypass. All patients had severe suprasystemic pulmonary artery pressures after
rotamine administration for heparin reversal, a complication that proved fatal in all
ases. Intraoperative wedge biopsy of the lungs revealed multiple microthrombi
ithin capillaries and in the small- and medium-sized pulmonary arterioles.
onclusion: We report 9 cases for which fatal pulmonary microthrombi might be
ssociated with the use of prophylactic antifibrinolytic therapy. Mortally ill patients
ith multiorgan failure who are receiving systemic anticoagulation and undergoing
urgical procedures require careful perioperative monitoring to identify potential
azards. Anticoagulation and antifibrinolytic therapy protocols may require adjust-
ent in such patients.
urgical therapy for critically ill patients with heart failure is associated with
a variety of complications. In 1997, one of the authors (O.H.F.) experienced
a mortality in a high-risk patients after insertion of a left ventricular assist
evice (LVAD) who experienced suprasystemic pulmonary artery pressures and in
hom right heart failure was impossible to overcome despite insertion of a right
entricular assist device (RVAD). A frozen section performed on an intraoperative
edge biopsy specimen of the lung showed, on close inspection, multiple recent
icrothrombi in the small vessels, a finding not previously identified in such
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CSPatients. During the next 7 years, we identified 8 additional
uch patients. In all of these patients, antifibrinolytic therapy
as administered immediately before and throughout the
ardiopulmonary bypass (CPB) period. Intraoperative fro-
en section and postmortem examination confirmed the
resence of multiple microthrombi within the capillaries
nd small- and occasionally medium-sized pulmonary
rterioles.
ethods
e reviewed our database, patient records, and autopsy reports to
dentify patients who had died either immediately or soon after
ndergoing surgical treatment for end-stage heart failure and who
ad associated pulmonary microthrombi with suprasystemic pul-
onary artery pressure. Data collected included age, sex, weight,
edical history, diagnosis, operative procedure and urgency, and
uration of CPB. All drugs administered intraoperatively, results
f intraoperative coagulation tests, operative complications (in-
luding bleeding), and all allogeneic blood transfusions were re-
iewed. Categoric variables are described by frequency (in per-
entages), and continuous measures are described as the mean 
tandard deviation.
Abbreviations and Acronyms
ACT  activated clotting time
ATIII  antithrombin III
CPB  cardiopulmonary bypass
DIC  disseminated intravascular coagulopathy
EACA  -aminocaproic acid
FFP  fresh frozen plasma
IABP  intra-aortic balloon pump
kACT  kaolin-activated clotting time
KIU  kallikrein inactivation unit
LVAD left ventricular assist device
RVAD right ventricular assist device
ABLE 1. Patient demographics and procedural data
Patient no. Sex Age (y) Weight (kg)
1 M 53 66
2 M 42 71
3 M 19 68
4 M 60 82
5 M 55 62
6 F 47 101
7 M 56 80
8 F 56 70
9 M 20 100
PB, Cardiopulmonary bypass; HT, heart transplantation; HDP, high-dose
-aminocaproic acid; LVAD, left ventricular assist device; MVR, mitral valve rep
64 The Journal of Thoracic and Cardiovascular Surgery ● Mayesults
atients
e identified 9 patients (7 men and 2 women; mean age, 45
16 years; range, 19-60 years) who died either during or
mmediately after cardiac surgery between January 1997
nd January 2004 whose frozen section wedge lung biopsy
pecimens showed extensive microthrombi in the pulmo-
ary vasculature. Patient demographics and procedural data
re presented in Table 1.
All patients were referred for surgical treatment of severe
nd-stage heart failure (New York Heart Association func-
ional class IV) caused by dilated cardiomyopathy. All 9
atients had undergone previous cardiac procedures, and of
hese patients, 5 had received preoperative circulatory sup-
ort with an intra-aortic balloon pump (IABP). All patients
ad hepatic and renal dysfunction at the time of surgical
ntervention. All 9 patients had received long-term oral
nticoagulation with warfarin in association with their
eart failure treatment. Seven patients received intrave-
ous heparin therapy. Neither the patients nor their blood
elatives had any preexisting history of deep venous
hrombosis, pulmonary emboli, or stroke preoperatively.
reoperative characteristics were not significant for allergic
eactions to drugs. Routine coagulation monitoring was
erformed in all patients.
All 9 patients had advanced cardiac failure requiring
harmacologic support to maintain cardiac output. In addi-
ion, 7 of the 9 patients required preoperative IABP coun-
erpulsation; 2 patients arrived in the operating room with
ardiopulmonary resuscitation in progress (Table 2).
urgical Procedures
ive of the 9 patients underwent LVAD implantation, 2
nderwent heart transplantation, and the remaining 2
nderwent left ventricular reconstruction with mitral
alve repair or replacement (Table 1).
Procedure
Initial duration of
CPB (min) Antifibrinolytic
HT 106 Aprotinin (HDP)
HT 125 Aprotinin (HDP)
LVR MVP 167 EACA
LVAD 74 Aprotinin (HDP)
LVR MVR 136 Aprotinin (BWP)
LVAD 177 Aprotinin (HDP)
LVAD 90 Aprotinin (BWP)
LVAD 71 Aprotinin (BWP)
LVAD 84 Aprotinin (BWP)
col; LVR, left ventricular reconstruction; MVP, mitral valvuloplasty; EACA,proto
lacement; BWP, body-weight protocol.
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PAll procedures were performed with membrane oxygen-
tors. The CPB circuit was primed either with electrolyte
olution (5 patients) or fresh frozen plasma (FFP; 4 pa-
ients). Packed red blood cells were added to the pump only
f the patient’s hemoglobin level was less than 6 g/dL at
0°C. Anesthesia induction was performed with etomidate
r thiopental plus fentanyl (5-10 mg/kg). Low-dose isoflu-
ane (0.4%-1.0%) was used for anesthesia maintenance and
as supplemented with midazolam (5-10 mg) and fentanyl
5-10 mg/kg). Anticoagulation was achieved with heparin
3 mg/kg or 300 U/kg body weight). Additional heparin was
dministered to maintain the kaolin-activated clotting time
kACT) at longer than 450 to 500 seconds. At the end of the
PB period, intravenous protamine sulfate was adminis-
ered for heparin reversal. Two patients were systemically
ooled by means of CPB (approximately 28°C), and the
thers underwent the procedure under hypothermic (34°C)
onditions. All patients were rewarmed to a nasopharyngeal
emperature of 36.5°C before being weaned from CPB.
edian initial CPB time was 114 minutes (range, 71-177
inutes). After discontinuation of CPB, there was no gross
vidence of thrombus in any perfusion circuit.
ABLE 3. ACT monitoring and heparin infusions during CP
Patient Antifibrinolytic kACT
1 Aprotinin 624-430-507
2 Aprotinin 415/400-711-836-724-604
3 EACA 480-406-400-294-403-521
4 Aprotinin 484-463-433-452-338
5 Aprotinin 362-375-419-400-497-474
6 Aprotinin 999-536-587-716-587-758
7 Aprotinin 740-387-443-553-608-576
8 Aprotinin 999-999-999-999-999-999
9 Aprotinin 571-655-660-494-306
ABLE 2. Preoperative patient condition and intervention
atient no. Diagnosis Planned procedure
1 CMP (ISC) HT CHF, h
2 CMP post-LVR HT CHF, re
3 CMP postcardiac trauma LVR MVP Ventric
4 CMP (ISC) post-LVR LVAD CHF, re
5 CMP LVR  MVR CHF
6 CMP post-HHT LVAD CHF
7 CMP LVAD CHF, c
failu
8 CMP LVAD CHF, re
failu
9 CMP LVAD CHF, h
MP, Cardiomyopathy; ISC, ischemic; HT, heart transplantation; CHF, con
lasty; CPR, cardiopulmonary resuscitation; OR, operating room; LVAD, le
eplacement; HHT, heterotopic heart transplant.CT, Activated clotting time; CPB, cardiopulmonary bypass; kACT, kaolin-activa
The Journal of ThoracicIn an effort to decrease postoperative bleeding, 8 patients
eceived aprotinin, and 1 patient received -aminocaproic
cid (EACA) (25-g total dose). Of the patients who received
protinin, 4 received the high-dose aprotinin protocol: a
-mL (10,000 kallikrein inactivation unit [KIU]) test dose, a
00-mL (2.0 million KIU) loading dose, and a 50 mL/h
500,000 KIU/h) continuous infusion. On initiation of CPB,
n additional 200 mL (2.0 million KIU) was added to the
PB priming fluid. In the other 4 patients, aprotinin was
dministered according to a weight-based protocol; the
oading dose and CPB priming doses were 100 mL each.
hree of the 8 patients who received aprotinin had prior
xposure to aprotinin (3, 5, and 32 days) before the current
peration.
Average blood use was 15  10 units of red blood cells,
7  17 units of FFP, and 18  13 units of platelets. (One
atient was a Jehovah’s Witness.) Cell saver was used in all
atients. Salvaged blood was washed and returned to the
atients.
Continuous monitoring of heparinization with kACT
as performed in all patients. Additional heparin was
dded when needed to keep the activated clotting time
Heparin (mg)
210
2105050
200
250
425 1905050
656-733-700-631 300-50-50
909 30010105010050505050
270270
300100100
operative condition Preoperative intervention
nsive Inotropes
ysfunction Diuretics, antidiuretics, -blockers
fibrillation CPR in progress in OR, vasopressors
tory failure, renal failure IABP, inotropes, vasopressors
IABP, inotropes
Inotropes
c arrest, respiratory CPR in progress in OR, IABP,
vasopressors
tory failure, hepatic IABP, vasopressors
c failure, renal failure IABP, vasopressors, inotropes
e heart failure; LVR, left ventricular reconstruction; MVP, mitral valvulo-
tricular assist device; IABP, intra-aortic balloon pump; MVR, mitral valveB
(s)
-636
-437-
-734-
-666-Pre
ypote
nal d
ular
spira
ardia
re
spira
re
epati
gestiv
ft vented clotting time; EACA, -aminocaproic acid.
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CSPACT) in the target range, but there was some variation in
he ACT value (in 6 of the 9 patients, the kACT was 450
econds for short periods). In addition, the timing of the
easurement of the kACT was inconsistent (Table 3). After
ompletion of the procedure and decannulation, hepariniza-
ion was reversed with protamine.
In all patients, within minutes of protamine administra-
ion, pulmonary artery pressure dramatically increased. In 1
atient after RVAD placement, a direct pressure measure-
ent was greater than 300 mm Hg (the limit of pressure that
ould be generated by the device). In all patients the pulmo-
ary artery pressure was suprasystemic. Right ventricular
istension and lack of right ventricular wall motion was
bserved. All patients again received heparin, full CPB was
einitiated, and RVAD implantation was performed. Despite
igure 1. Three adjacent pulmonary capillaries occluded by fibrin
hrombi (A, hematoxylin and eosin stain, original magnification
00; B, periodic acid–Schiff stain, original magnification 600).VAD support, 8 of the 9 patients died in the operating h
66 The Journal of Thoracic and Cardiovascular Surgery ● Mayoom. One patient received fibrinolytic therapy (tissue-type
lasminogen activator), which reversed the pulmonary hy-
ertension, but the patient died of exsanguination in the
ntensive care unit.
athologic Findings
ostmortem examinations were limited to the heart and
ungs in 7 patients, and complete autopsies were performed
n 2 patients. In all patients the histology was identical.
icroscopically, there were multiple recent thrombi, which
ppeared to be composed of fibrin (with no obvious cellular
omponent) present in the capillaries and small- and medi-
m-sized pulmonary arterioles throughout both lungs (Fig-
re 1). Three patients also were noted to have microthrombi
resent within the epicardial and intramyocardial microvas-
ulature. In the 2 patients in whom full autopsies were
erformed, microthrombi were not noted in other organs.
iscussion
ibrin microthrombi are a localized expression of a sys-
emic process, such as disseminated intravascular coagu-
opathy (DIC). They have been found in various organs,
ncluding the lungs, in organ rejection episodes and in a
ariety of disease entities, such as DIC or hemolytic anemia
yndrome among others, and are not thought to be an embolic
henomenon.
The clinical presentation of the patients in this series
oes not, in our view, reflect an embolic cause. All patients
ad been successfully weaned from CPB (with some ino-
ropic support and, for some, IABP support) and had had
heir venous cannulas removed. Only after protamine rever-
al of heparin did the catastrophic pulmonary hypertension
nd subsequent right ventricular failure result. The fact that
VAD use was not able to overcome the increased pulmo-
ary resistance, coupled with the uniform lack of response
o pharmacologic therapy for pulmonary hypertension, speaks
o the extent of the microthrombi occlusion of pulmonary
rterioles and capillaries.
The overriding clinical presentation characterized by
omplete blockage of meaningful pulmonary blood flow has
ot been experienced at our institution and has no clinical
ompatibility with the hypotensive response occasionally
een with protamine administration. This dramatic cessation
f pulmonary blood flow is unique in the experience of the
enior author (O.H.F.), who was present during all of the
ases in this report and has performed more than 500 LVAD
mplantations and more than 900 heart transplantation
rocedures.
In general, cardiac surgery is associated with an initial
ypocoagulable state, although hypercoagulability might man-
fest later in the postoperative period. Many factors contrib-
te to intraoperative and postoperative bleeding, including
eparin use, platelet dysfunction, protein denaturation by
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Peans of CPB, hemodilution, hypothermia, inflammatory
ediator release, and hyperfibrinolysis. Preoperative fac-
ors, such as liver and renal dysfunction and anticoagulant
se, might also contribute to postoperative bleeding.
In an effort to combat bleeding after CPB, pharmaco-
ogic therapy has been used as an adjunct to other measures,
n particular to address hyperfibrinolysis. Antifibrinolytic ther-
py reduces hyperfibrinolysis and mitigates inflammatory
isturbances that might contribute to coagulopathy.1 The
erioperative use of antifibrinolytic drugs, such as aprotinin
r EACA, reduces the incidence of blood loss, allogeneic
lood transfusion, mediastinal re-exploration, and mortality
fter cardiac surgery.2-6
In all patients described in this report, antifibrinolytic
herapy was administered. Several reports exist in the liter-
ture about thrombotic complications associated with the
se of antifibrinolytics. Heindel and colleagues7 report a
ase of fatal systemic thrombosis associated with aprotinin
se and heparin-protamine reversal during a hemi-Fontan
rocedure. Other investigators report an increased tendency
oward thrombosis-related complications associated with
protinin, including myocardial infarction,8 early saphenous
ein graft thrombosis,9-11 thrombi formation on the pulmo-
ary artery catheter after CPB,12 and fatal pulmonary em-
olism during liver transplantation.13-15 Another report of a
assive intravascular thrombosis after cardiac arrest in a
atient treated with EACA also raises concern about the
gents used for antifibrinolytic therapy.16 However, in a
eta-analysis by Levi and associates,2 the use of aprotinin
uring cardiac surgery was not associated with an increased
isk of perioperative myocardial infarction. Furthermore, it
as been demonstrated that aprotinin normally seems to be
imultaneously hemostatic and antithrombotic because it
electively blocks the proteolytically activated thrombin
eceptor on platelets but leaves other mechanisms of platelet
ggregation unaffected.17
Further controversy revolves around the amount of anti-
brinolytic agent that should be used, especially in the case
f aprotinin. High-dose, low-dose, and weight-based proto-
ols have been advocated. Four of the patients in this series
eceived the high-dose protocol, and 4 received a weight-
ased protocol, challenging the association of the amount of
protinin administered as being a significant factor in the
linical course of these patients.
Anticoagulation management during CPB is controver-
ial, especially when using a potentially unreliable test, such
s ACT, in the presence of aprotinin.18,19 Current recom-
endations suggest that heparin be administered with the
oal of a celite ACT of greater than 750 seconds20 and a
ACT of greater than 480 seconds, although these values
re arbitrary and controversial.21 EACA does not interfere
ith the kACT measurement in the presence of heparin.22 In
ur patients additional heparin was used to maintain the a
The Journal of ThoracicACT at greater than 480 seconds; however, in some cases
here were short periods when the kACT did not reach this
evel. In others the kACT values were consistently high,
hich, by conventional standards, indicates that hepariniza-
ion was adequate.
Most of the patients in the case reports or series cited
arlier had gross systemic or venous thrombosis, which is a
linically different presentation than we observed. However,
ecause we were clearly unable to achieve transpulmonary
lood flow, it is not surprising that the microthrombi would
e limited to the lungs. Sundt and coworkers23 report the
resence of platelet-fibrin thrombi in a series of patients in
hom aprotinin and hypothermic circulatory arrest were
sed. In that study the platelet-fibrin thrombi were found
n multiple organs, but in 2 patients there was significant
ulmonary involvement. Of these patients, 1 died intraop-
ratively of acute right ventricular failure. Like Sundt and
oworkers, we have not observed this complication in any
f our patients of this type in whom aprotinin or EACA was
ot used. In addition, we have only observed it in 9 patients.
e do not routinely use antifibrinolytics in all critically ill
atients, and therefore the denominator population for this
eport is unknown; however, we do routinely prime the CPB
ircuit with FFP and avoid use of electrolyte solutions in
atients with advanced heart failure.
Although antifibrinolytic therapy might be a factor in this
yndrome, clearly others must also be involved. First, all
atients in this group had poor cardiac function (resulting in
ow cardiac output), liver and renal dysfunction, and poor
eripheral perfusion. Although liver and renal dysfunction
enerally promote hypocoagulability through a variety of
echanisms, they also might promote hypercoagulation
hrough decreased production of endogenous anticoagulant
actors and decreased clearance of activated procoagulants,
roducing DIC. However, it does not usually present with
uch a catastrophic effect.
Second, those endogenous anticoagulant factors might have
een affected by other interventions. Preoperative heparin
reatment induces decreased antithrombin III (ATIII) activ-
ty, which might result in a reduced sensitivity to heparin
uring CPB.24,25 In addition, hemodilution and ATIII con-
umption induced by CPB could cause ATIII levels to
urther decrease. Even in the presence of high heparin
oncentrations, the monitoring and substitution of ATIII
ppears to ensure more efficient antithrombin activity dur-
ng CPB.26 Although ATIII levels were not routinely mea-
ured in our patients, multiple FFP transfusions were given,
nd the CPB circuit was primed with FFP in 4 patients,
hich argues against ATIII depletion as a contributing
actor.
Other endogenous anticoagulant factors, such as proteins
and S, when deficient, can be associated with hyperco-gulation. Pathologic states, such as the antiphospholipid
and Cardiovascular Surgery ● Volume 131, Number 5 967
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CSPyndrome or the presence of Factor V Leiden, might also be
ssociated with hypercoagulability; unfortunately, their pres-
nce or absence was not measured in our patients, and
herefore their effect is unknown.
Although this report is limited by its retrospective and
bservational nature, we believe these patients represent a
nique syndrome. Therefore we believe it is important to
eport these observations.
onclusions
he value of antifibrinolytic therapy in reducing blood loss
as clearly been demonstrated. To safely extend its use in
hese critically ill patients, however, requires careful peri-
perative monitoring to identify any potential hazards, so
hat anticoagulation and antifibrinolytic therapy protocols
an be adjusted accordingly. Particular attention should be
aid to adequate heparinization throughout the sometimes
rolonged CPB times required for performing complicated
rocedures in patients with advanced heart failure. Consid-
ration should be given to continuous heparin infusion
uring CPB to avoid even short periods of undetected
nadequate heparinization. In most patients extensive bleed-
ng can be dealt with successfully, but extensive thrombosis
as fatal in these patients.
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